Navigation Links
Particle Sciences and Pernix Therapeutics Enter into an Agreement to Develop a Pediatric Dermatology Product
Date:3/21/2012

BETHLEHEM, Pa., March 21, 2012 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, today announced that it is developing with Pernix Therapeutics, a specialty pharmaceutical company, a new topical dermatology product for the pediatric market.

Mark Mitchnick, CEO of Particle Sciences, said, "There are multiple treatments for many pediatric skin conditions.  The unmet need is in the delivery of these agents via a more convenient, and improved vehicle.  Particle Sciences is applying advanced drug delivery and formulation technologies to an established pediatric product category.  For parents, this product is designed to be a potentially better and easier to use product."

Cooper Collins, Pernix Therapeutics' President and CEO, said, "We are enthusiastic about working with Particle Sciences for this product candidate, which may be another opportunity to further expand our pediatric product line."

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.comor contact us at (610) 861-4701 for information.

Contact:  Maureen Mattera, (610) 861-4701, mmattera@particlesciences.com


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Particle Sciences Hires Robert Gwozdz to Head Oral Formulation
4. Brabender® Pharma USA, Inc. and Particle Sciences Cooperate to Expand Extrusion Capabilities
5. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
6. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
7. Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services
8. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
9. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
10. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
11. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 2017 , ... The Ellis Agency, an eastern Georgie provider of insurance management ... wide charity event with the goal of bringing in support for epilepsy patients in ... with epilepsy, recently launched a charity campaign of her own by donating her birthday ...
(Date:7/21/2017)... ... , ... Fresh Wave® IAQ today announced the launch of its innovative ... at the APPA 2017 Annual Conference and Exhibition in Booth #414. , ... the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm ... the contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces ... Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how ... their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. ... on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... cruciate ligament (ACL) offer patients improved quality of life five years after injury, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients for ...
Breaking Medicine News(10 mins):